West Deptford, N.J. – 11 January 2017, Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, is pleased to announce the launch of its new online catalyst store. The store has been introduced to provide customers with easy access to research quantities of commercial grade ligands and catalysts, to accelerate development of efficient and economic processes to pharmaceuticals, agrochemicals, and other applications.

Royston, UK. 15 December, 2016 – Johnson Matthey (LSE: JMAT), a leader in science and technologies that make the world cleaner and healthier, announced today that Robert MacLeod, Chief Executive of Johnson Matthey, and John Fowler, Divisional Director of Johnson Matthey Fine Chemicals, are visiting the company’s Annan site in Scotland to meet with local dignitaries and journalists.

West Deptford, N.J. – 20 September, 2016 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, announced today that its facilities in Annan, UK, have been approved for GMP manufacturing following an extensive programme of renovation and refitment. Johnson Matthey acquired the Annan facility in November 2014 in order to expand the Fine Chemicals Division’s large volume capacity, in response to customer demand for controlled substance APIs and custom manufacturing services.

Last week on Wednesday 4th May, Johnson Matthey Fine Chemicals held the official opening of its recently expanded Cambridge facility. The day gave attendees the opportunity to tour both old and new areas of the facility and listen to presentations from industry experts. The extremely successful event was well attended by over 50 customers, industry representatives and journalists, as well as Johnson Matthey staff and scientists.

Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies and Domainex Ltd. (Cambridge, UK), a small-molecule drug discovery company, have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services. The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the UK and beyond with effective, simplified, rapid and reduced risk target-to-lead identification, optimisation, safety/toxicology, pre-clinical and clinical API supply services.

West Deptford, N.J. – Wednesday 20th January, 2016 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has completed an expansion of its Cambridge, UK facilities, bringing additional process research & development services and kilo-scale manufacture to the growing site. This investment supports the use of Johnson Matthey’s world-leading catalyst and biocatalyst technology in process R&D and non-GMP production of materials for pre-clinical pharmaceutical and toxicology studies.

West Deptford, N.J. – 1st October, 2015 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has acquired the Pharmorphix® solid form research business from Sigma-Aldrich. This acquisition brings world-leading material science capabilities to Johnson Matthey’s expanding European API and clinical supply services.

West Deptford, N.J. – 15th September 2015 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has today unveiled the distinctive new branding for its Fine Chemicals Division.

West Deptford, N.J. – March 12, 2015 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has been recognised in the 2015 CMO Leadership Awards for the Reliability and Regulatory Track record of its Pharma Services to the Biotech Industry.

West Deptford, N.J. – March 10, 2015 – Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion and commissioning of new high containment facilities for potent product manufacture at its Edinburgh, UK site (Macfarlan Smith).